Searched for
MURALI DIVI INCOME
Sell Divi's Laboratories, target price Rs 4,500: ICICI SecuritiesICICI Securities recommends a sell on Divi's Laboratories with a target price of Rs 4,500 despite recent quarterly growth. Management remai...- Buy Divi's Laboratories, target price Rs 3576: ICICI DirectDivi's Laboratories, incorporated in the year 1990, is a Large Cap company (having a market cap of Rs 94817.41 Crore) operating in Pharmace...
- Buy Divi's Laboratories, target price Rs 3730: ICICI SecuritiesDivi's Laboratories, incorporated in the year 1990, is a Large Cap company (having a market cap of Rs 94466.99 Crore) operating in Pharmace...
- Buy Divi's Laboratories, target price Rs 3579: ICICI DirectDivi's Laboratories, incorporated in the year 1990, is a Large Cap company (having a market cap of Rs 93390.52 Crore) operating in Pharmace...
- Buy Divi's Laboratories, target price Rs 2912: ICICI DirectDivi's Laboratories, incorporated in the year 1990, is a Large Cap company (having a market cap of Rs 76314.25 Crore) operating in Pharmace...
- Saurabh Mukherjea is gung-ho on 2 pharma stocks; adds Prudent Corporate. Here’s whyFounder of Marcellus Investment Managers, Saurabh Mukherjea, advises investors to identify businesses with unique skill sets and distinctiv...
- Motilal Oswal Financial Services neutral on Divi's Laboratories, target price-Rs 2620Promoters held 51.94 per cent stake in the company as of 31-Dec-2022, while FIIs owned 15.15 per cent, DIIs 20.5 per cent.
- Sell Divi's Laboratories, target price Rs 2750: Sharekhan by BNP ParibasDivi's Laboratories, incorporated in the year 1990, is a Large Cap company (having a market cap of Rs 75747.48 Crore) operating in Pharmace...
- Buy Divi's Laboratories, target price Rs 3480: Reliance SecuritiesDivi's Laboratories, incorporated in the year 1990, is a Large Cap company (having a market cap of Rs 90499.57 Crore) operating in Pharmace...
- At Rs 58.8 cr, Murali of Divi's Lab highest paid Indian pharma executiveThe percentage increase in the median remuneration for the staff of the firm for FY19 was 3.96 per cent.
Load More
